Outcome of human umbilical cord blood stem cell transplantation (CBT) for acute myeloid leukemia in patients achieving first complete remission after one versus two induction courses: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
Nagler, Arnon; Labopin, Myriam; Cornelissen, Jan Jet al.
2022 • In Bone Marrow Transplantation, 57 (10), p. 1514-1519
[en] We compared transplantation outcomes of adult patients with AML that underwent cord blood transplantation (CBT) in CR1 following 1 versus 2 induction courses. Study included 325 patients, 243 (75%) with 1 and 82 (25%) with 2 induction courses. Engraftment was lower for patients achieving CR1 after 1 vs. 2 induction courses: 91% vs. 99% (p = 0.02). Incidence of acute GVHD was similar, 38% and 36% (p = 0.81), as was 2-year chronic GVHD at 23.4% and 27.5%, respectively (p = 0.65). Two-year non-relapse mortality (NRM), relapse incidence (RI), leukemia-free survival (LFS), overall survival (OS) and GVHD-free, relapse-free survival (GRFS) were not statistically different between patients achieving CR1 with 1 vs. 2 induction courses with 23% vs. 24% (p = 0.87), 25% vs. 30% (p = 0.4), 52% vs. 46% (p = 0.3), 59% vs. 50% (p = 0.2), and 44% vs. 41% (p = 0.66), respectively. Results were confirmed by multivariable analysis, NRM (hazard ratio (HR) = 1.1; 95% CI, 0.6-1.8, p = 0.7), RI (HR = 1.4; 95% CI, 0.9-2.3, p = 0.1), LFS (HR = 1.3; 95% CI, 0.9-1.8, p = 0.2), OS (HR = 1.3; 95% CI, 0.9-1.9, p = 0.1), and GRFS (HR = 1.1; 95% CI, 0.8-1.5, p = 0.5). Overall, outcomes of AML patients undergoing CBT in CR1 achieved after 1 or 2 induction courses are similar.
Disciplines :
Hematology
Author, co-author :
Nagler, Arnon ; Division of Hematology, Sheba Medical Center, Tel Hashomer, Israel.
Labopin, Myriam; EBMT Paris study office, Department of Hematology, Saint Antoine Hospital, ; Sorbonne University, Department of Hematology, Saint Antoine Hospital, INSERM UMR
Cornelissen, Jan J; Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of
Forcade, Edouard; CHU Bordeaux, Hôpital Haut-Leveque, Pessac, France.
Chevallier, Patrice; CHU Nantes Department, D'Hematologie, Nantes, France.
Fegueux, Nathalie; CHU Lapeyronie, Département d'Hématologie Clinique, Montpellier, France.
Sierra, Jorge; Hospital Santa Creu i Sant Pau Hematology Department, Barcelona, Spain.
Desmier, Deborah; Hopital La Miletrie, Head of the Bone Marrow Transplant Unit, Clinical
Labussière-Wallet, Hélène; Centre Hospitalier Lyon Sud, Pavillon Marcel Bérard, Service Hematologie, Lyon,
Byrne, Jenny L ; Nottingham University, Nottingham, UK.
Loschi, Michael ; Cote d'Azur University, Hematology department, Nice University Hospital, Nice
Blaise, Didier; Programme de Transplantation & Therapie Cellulaire, Centre de Recherche en
Baron, Frédéric ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'hématologie clinique
Ruggeri, Annalisa; Department of Pediatric Hematology and Oncology, IRCCS Ospedale Pediatrico
Mohty, Mohamad; Department of Hematology, Hospital Saint Antoine, EBMT Paris Study
Outcome of human umbilical cord blood stem cell transplantation (CBT) for acute myeloid leukemia in patients achieving first complete remission after one versus two induction courses: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
Dholaria B, Savani BN, Hamilton BK, Oran B, Liu HD, Tallman MS, et al. Hematopoietic cell transplantation in the treatment of newly diagnosed adult acute myeloid leukemia: an evidence-based review from the American Society of Transplantation and Cellular Therapy. Transplant Cell Ther. 2021;27:6–20. DOI: 10.1016/j.bbmt.2020.09.020
Gragert L, Eapen M, Williams E, Freeman J, Spellman S, Baitty R, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med. 2014;371:339–48. DOI: 10.1056/NEJMsa1311707
Eapen M, Klein JP, Ruggeri A, Pellman S, Lee SJ, Anasetti C, et al. Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. Blood. 2014;123:133–40. DOI: 10.1182/blood-2013-05-506253
Shouval R, Ruggeri A, Labopin M, Mohty M, Sanz G, Michel G, et al. An integrative scoring system for survival prediction following umbilical cord blood transplantation in acute leukemia. Clin Cancer Res. 2017;23:6478–86. DOI: 10.1158/1078-0432.CCR-17-0489
Stanevsky A, Shimoni A, Yerushalmi R, Nagler A. Cord blood stem cells for hematopoietic transplantation. Stem Cell Rev Rep. 2011;7:425–33. DOI: 10.1007/s12015-010-9183-9
Baron F, Ruggeri A, Beohou E, Labopin M, Sanz G, et al. RIC versus MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMT. Oncotarget. 2016;7:43027–38. DOI: 10.18632/oncotarget.9599
Eapen M, Rocha V, Sanz G, Scaradavou A, Zhang MJ, Arcese W, et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol. 2010;11:653–60. DOI: 10.1016/S1470-2045(10)70127-3
Ruggeri A, Labopin M, Sanz G, Piemontese S, Arcese W, Bacigalupo A, et al. Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia. Leukemia. 2015;29:1891–900. DOI: 10.1038/leu.2015.98
Baron F, Labopin M, Ruggeri A, Cornelissen JJ, Meijer E, Sengeloev H, et al. Impact of donor type in patients with AML given allogeneic hematopoietic cell transplantation after low-dose TBI-based regimen. Clin Cancer Res. 2018;24:2794–803. DOI: 10.1158/1078-0432.CCR-17-3622
Milano F, Gooley T, Wood B, Woolfrey A, Flowers ME, Doney K, et al. Cord-blood transplantation in patients with minimal residual disease. N Engl J Med. 2016;375:944–53. DOI: 10.1056/NEJMoa1602074
Baron F, Labopin M, Ruggeri A, Sierra J, Robinson S, Labussière-Wallet H, et al. Impact of detectable measurable residual disease on umbilical cord blood transplantation. Am J Hematol. 2020;95:1057–65. DOI: 10.1002/ajh.25879
Baron F, Ruggeri A, Beohou E, Labopin M, Mohty M, Sanz J, et al. Occurrence of graft-versus-host disease increases mortality after umbilical cord blood transplantation for acute myeloid leukaemia: a report from Eurocord and the ALWP of the EBMT. J Intern Med. 2018;283:178–89. DOI: 10.1111/joim.12696
Lamers CH, Wijers R, van Bergen CA, Somers JA, Braakman E, Gratama JW, et al. CD4+ T-cell alloreactivity toward mismatched HLA class II alleles early after double umbilical cord blood transplantation. Blood 2016;128:2165–74. DOI: 10.1182/blood-2016-06-718619
Baron F, Labopin M, Ruggeri A, Ehninger G, Bonifazi F, Stelljes M, et al. Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the EBMT. Blood Cancer J. 2019;9:46. DOI: 10.1038/s41408-019-0204-x
Shanmuganathan N, Pagani IS, Ross DM, Park S, Yong ASM, Braley JA, et al. Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia. Blood. 2021;137:1196–207. DOI: 10.1182/blood.2020005514
Sharvit G, Heering G, Zlotnik M, Merkel D, Nagler A, Avigdor A, et al. Acute myeloid leukemia patients requiring two cycles of intensive induction for attainment of remission experience inferior survival compared with patients requiring a single course of induction chemotherapy. Clin Lymphoma Myeloma Leuk. 2021;S2152-2650:02017–6.
Nagler A, Labopin M, Huang XJ, Blaise D, Arcese W, Araujo MC, et al. Non-T depleted Haploidentical Stem Cell Transplantation in AML patients achieving first complete remission after one versus two induction courses: a study from the ALWP/EBMT. Bone Marrow Transplant. 2022;57:572–8.
Nagler A, Baron F, Labopin M, Polge E, Esteve J, Bazarbachi A, et al. Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT. Bone Marrow Transplant. 2021;56:218–24. DOI: 10.1038/s41409-020-01005-y
Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628–33. DOI: 10.1016/j.bbmt.2009.07.004
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–8.
Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinic pathologic study of 20 Seattle patients. Am J Med. 1980;69:204–17. DOI: 10.1016/0002-9343(80)90380-0
Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. Bone Marrow Transplant. 2016;51:610–1. DOI: 10.1038/bmt.2015.305
Abraham SK, Arnon N, Bipin S. Summary of scientific and statistical methods, study endpoints and definitions for observational and registry-based studies in hematopoietic cell transplantation. Clin Hematol Int. 2019;2:2–4. DOI: 10.2991/chi.d.191207.001
Andersen PK, Klein JP, Zhang MJ. Testing for center effects in multi-center survival studies: a Monte Carlo comparison of fixed and random effects tests. Stat Med. 1999;18:1489–500. DOI: 10.1002/(SICI)1097-0258(19990630)18:12<1489::AID-SIM140>3.0.CO;2-#
R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2017. https://www.R-project.org/.
Ferguson P, Hills RK, Grech A, Betteridge S, Kjeldsen L, Dennis M, et al. An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation. Haematologica. 2016;101:1351–8. DOI: 10.3324/haematol.2016.148825
Lim SJ, Lim MJ, Raptis A, Hou JZ, Farah R, Marks SM, et al. Inferior outcome after allogeneic transplant in first remission in high-risk AML patients who required more than two cycles of induction therapy. Am J Hematol. 2015;90:715–8. DOI: 10.1002/ajh.24062
Walter RB, Sandmaier BM, Storer BE, Godwin CD, Buckley SA, Pagel JM, et al. Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission. Biol Blood Marrow Transplant. 2015;21:373–8. DOI: 10.1016/j.bbmt.2014.09.022
Canaani J, Labopin M, Itälä-Remes M, Blaise D, Socié G, Forcade E, et al. Prognostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia. Leukemia. 2019;33:1944–52. DOI: 10.1038/s41375-019-0439-3
Dholaria B, Labopin M, Sanz J, Ruggeri A, Cornelissen J, Labussière-Wallet H, et al. Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia. J Hematol Oncol. 2021;14:76. DOI: 10.1186/s13045-021-01086-2
Ruggeri A, Sanz G, Bittencourt H, Sanz J, Rambaldi A, Volt F, et al. Eurocord and Acute Leukemia Working Party of European Blood and Marrow Transplant Group. Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT. Leukemia. 2014;28:779–86. DOI: 10.1038/leu.2013.259
Baron F, Ruggeri A, Beohou E, Labopin M, Mohty M, Blaise D, et al. Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMT. J Hematol Oncol. 2017;10:128. DOI: 10.1186/s13045-017-0497-9
Admiraal R, Lindemans CA, van Kesteren C, Bierings MB, Versluijs AB, Nierkens S, et al. Excellent T-cell reconstitution and survival depend on low ATG exposure after pediatric cord blood transplantation. Blood. 2016;128:2734–41. DOI: 10.1182/blood-2016-06-721936
Kantarjian H, Kadia T, DiNardo C, Daver N, Borthakur G, Jabbour E, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11:41. DOI: 10.1038/s41408-021-00425-3
Baron F, Ruggeri A, Nagler A. Methods of ex vivo expansion of human cord blood cells: challenges, successes and clinical implications. Expert Rev Hematol. 2016;9:297–314. DOI: 10.1586/17474086.2016.1128321
Cohen S, Roy J, Lachance S, Delisle JS, Marinier A, Busque L, et al. Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study. Lancet Haematol. 2020;7:e134–45. DOI: 10.1016/S2352-3026(19)30202-9
